ArticlePancreas2014
PIK3CA mutations in mucinous cystic neoplasms of the pancreas.
Article in Pancreas, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 62 citations in OpenAlex.
- Mucinous cystic neoplasms and simple mucinous cysts are two distinct precursors of pancreatic cancer: clinicopathological, genomic, and transcriptomic characterization.The Journal of pathology · 2025Article
- Molecular Pathology of Pancreatic Cystic Lesions with a Focus on Malignant Progression.Cancers · 2024Review
- Pancreatic Cystic Lesions: A Focused Review on Cyst Clinicopathological Features and Advanced Diagnostics.Diagnostics (Basel, Switzerland) · 2022Review
- Laser Capture Microdissection: A Gear for Pancreatic Cancer Research.International journal of molecular sciences · 2022Review
- Early diagnosis of pancreatic cancer: What strategies to avoid a foretold catastrophe.World journal of gastroenterology · 2022Review
- RNF43 as a predictor of malignant transformation of pancreatic mucinous cystic neoplasm.Virchows Archiv : an international journal of pathology · 2022Article
- Non-coding RNA biomarkers in pancreatic ductal adenocarcinoma.Seminars in cancer biology · 2021Review
- Pancreatic cancer in 2021: What you need to know to win.World journal of gastroenterology · 2021Review
- Molecular alterations in pancreatic tumors.World journal of gastroenterology · 2021Review
- A mucinous cystic neoplasm of the pancreas containing an undifferentiated carcinoma component and harboring the NRAS driver mutation.Clinical journal of gastroenterology · 2021Article
- Biomarkers and Strategy to Detect Preinvasive and Early Pancreatic Cancer: State of the Field and the Impact of the EDRN.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020Article
- Molecular and Immunohistochemical Analysis of Mucinous Cystic Neoplasm of the Liver.American journal of clinical pathology · 2020Article
- Pancreatic Cysts in the Elderly.Current treatment options in gastroenterology · 2019Review
- Diagnosis and management of pancreatic cystic neoplasms: current evidence and guidelines.Nature reviews. Gastroenterology & hepatology · 2019Review
- Advanced diagnostics for pancreatic cysts: Confocal endomicroscopy and molecular analysis.World journal of gastroenterology · 2019Review
- Early Detection of Pancreatic Cancer: Opportunities and Challenges.Gastroenterology · 2019Review
- From somatic mutation to early detection: insights from molecular characterization of pancreatic cancer precursor lesions.The Journal of pathology · 2018Review
- Article
- Confocal endomicroscopy and cyst fluid molecular analysis: Comprehensive evaluation of pancreatic cysts.World journal of gastrointestinal endoscopy · 2018Review
- Novel Biomarkers for Pancreatic Cysts.Digestive diseases and sciences · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
objectivesMucinous cystic neoplasms (MCNs) are rare, potentially curable, mucin-producing neoplasms of the pancreas. We have previously reported PIK3CA (phosphoinositide-3-kinase catalytic subunit, p110α) mutations in intraductal papillary mucinous neoplasms, another mucin-producing neoplasm of the pancreas. In this study, we analyzed the presence of PIK3CA and AKT1/PKB (V-akt murine thymoma viral oncogene homolog 1) hot-spot mutations in MCN specimens.
methodsUsing the genomic DNA sequencing of tumor tissues isolated by laser capture microdissection, we evaluated 15 well-characterized MCNs for the E542K, E545K (exon 9), and H1047R (exon 20) hot-spot mutations in the PIK3CA gene and the E17K mutation in the AKT1 gene.
resultsA hot-spot mutation (E545K) of the PIK3CA gene was detected in 1 of the 15 MCNs and further confirmed by a mutant-enriched method. Interestingly, this mutation was found to be present only in the high-grade but not in low-grade dysplastic epithelium obtained from this neoplasm and coexisted with a KRAS mutation. No mutations were identified in the AKT1 gene.
conclusionsOur data, when combined with previous reports on intraductal papillary mucinous neoplasms, indicate that oncogenic activation of the PI3K pathway involving PIK3CA gene mutations can contribute to the progression of mucin-producing neoplasms but not pancreatic intraepithelial neoplasia. PIK3CA status could be useful for understanding their progression to malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.